CureDRPLA co-founders, Paul and Andrea Compton, have a son with DRPLA and their personal experiences with this devastating condition are the driving force behind CureDRPLA. Earlier this year, CureDRPLA announced that n-Lorem had an experimental treatment for DRPLA and that it was available to a handful of people with DRPLA in the United States.

In a podcast with Stan Crooke, CEO of n-Lorem, Paul Compton shared insights on his son’s progress since beginning treatment and what CureDRPLA envisions for the future.  

Watch or listen to the podcast here.